Emerging drugs for EGFR-mutated non-small cell lung cancer

Vineeth Sukrithan, Lei Deng, Alexander Barbaro, Haiying Cheng

Research output: Contribution to journalReview article

Abstract

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with metastatic non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. However, these agents are associated with inevitable treatment resistance. Newer generations of TKIs are under development that may prevent or overcome resistance and enhance intracranial activity. Areas covered: In this review, we will discuss newer generations of EGFR TKIs for EGFR-mutated NSCLC. We will also address resistance mutations and escape pathways associated with these agents such as secondary mutations, downstream signaling, bypass pathways, phenotypic transformation, anti-apoptotic signaling, immune evasion, and angiogenesis. Furthermore, this article encompasses emerging data from combination trials with next-generation TKIs that are being pursued to delay or prevent the occurrence of resistance. Expert opinion: The promise and challenge of precision oncology is encapsulated in the treatment of EGFR-mutated NSCLC with TKIs. Third generation TKIs have shown superior efficacy in the front-line setting and have become standard of care. A better understanding of mechanisms of treatment failure and disease relapse will be required to develop novel therapeutic strategies to further improve patient outcomes in the future.

Original languageEnglish (US)
Pages (from-to)5-16
Number of pages12
JournalExpert Opinion on Emerging Drugs
Volume24
Issue number1
DOIs
StatePublished - Jan 2 2019

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Pharmaceutical Preparations
Standard of Care
Mutation
Immune Evasion
Expert Testimony
Treatment Failure
Therapeutics
Recurrence

Keywords

  • EGFR
  • NSCLC
  • resistance mechanisms
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs for EGFR-mutated non-small cell lung cancer. / Sukrithan, Vineeth; Deng, Lei; Barbaro, Alexander; Cheng, Haiying.

In: Expert Opinion on Emerging Drugs, Vol. 24, No. 1, 02.01.2019, p. 5-16.

Research output: Contribution to journalReview article

Sukrithan, Vineeth ; Deng, Lei ; Barbaro, Alexander ; Cheng, Haiying. / Emerging drugs for EGFR-mutated non-small cell lung cancer. In: Expert Opinion on Emerging Drugs. 2019 ; Vol. 24, No. 1. pp. 5-16.
@article{014c64192bba499aae8cb3d3f6c674c9,
title = "Emerging drugs for EGFR-mutated non-small cell lung cancer",
abstract = "Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with metastatic non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. However, these agents are associated with inevitable treatment resistance. Newer generations of TKIs are under development that may prevent or overcome resistance and enhance intracranial activity. Areas covered: In this review, we will discuss newer generations of EGFR TKIs for EGFR-mutated NSCLC. We will also address resistance mutations and escape pathways associated with these agents such as secondary mutations, downstream signaling, bypass pathways, phenotypic transformation, anti-apoptotic signaling, immune evasion, and angiogenesis. Furthermore, this article encompasses emerging data from combination trials with next-generation TKIs that are being pursued to delay or prevent the occurrence of resistance. Expert opinion: The promise and challenge of precision oncology is encapsulated in the treatment of EGFR-mutated NSCLC with TKIs. Third generation TKIs have shown superior efficacy in the front-line setting and have become standard of care. A better understanding of mechanisms of treatment failure and disease relapse will be required to develop novel therapeutic strategies to further improve patient outcomes in the future.",
keywords = "EGFR, NSCLC, resistance mechanisms, tyrosine kinase inhibitors",
author = "Vineeth Sukrithan and Lei Deng and Alexander Barbaro and Haiying Cheng",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/14728214.2018.1558203",
language = "English (US)",
volume = "24",
pages = "5--16",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Emerging drugs for EGFR-mutated non-small cell lung cancer

AU - Sukrithan, Vineeth

AU - Deng, Lei

AU - Barbaro, Alexander

AU - Cheng, Haiying

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with metastatic non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. However, these agents are associated with inevitable treatment resistance. Newer generations of TKIs are under development that may prevent or overcome resistance and enhance intracranial activity. Areas covered: In this review, we will discuss newer generations of EGFR TKIs for EGFR-mutated NSCLC. We will also address resistance mutations and escape pathways associated with these agents such as secondary mutations, downstream signaling, bypass pathways, phenotypic transformation, anti-apoptotic signaling, immune evasion, and angiogenesis. Furthermore, this article encompasses emerging data from combination trials with next-generation TKIs that are being pursued to delay or prevent the occurrence of resistance. Expert opinion: The promise and challenge of precision oncology is encapsulated in the treatment of EGFR-mutated NSCLC with TKIs. Third generation TKIs have shown superior efficacy in the front-line setting and have become standard of care. A better understanding of mechanisms of treatment failure and disease relapse will be required to develop novel therapeutic strategies to further improve patient outcomes in the future.

AB - Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with metastatic non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. However, these agents are associated with inevitable treatment resistance. Newer generations of TKIs are under development that may prevent or overcome resistance and enhance intracranial activity. Areas covered: In this review, we will discuss newer generations of EGFR TKIs for EGFR-mutated NSCLC. We will also address resistance mutations and escape pathways associated with these agents such as secondary mutations, downstream signaling, bypass pathways, phenotypic transformation, anti-apoptotic signaling, immune evasion, and angiogenesis. Furthermore, this article encompasses emerging data from combination trials with next-generation TKIs that are being pursued to delay or prevent the occurrence of resistance. Expert opinion: The promise and challenge of precision oncology is encapsulated in the treatment of EGFR-mutated NSCLC with TKIs. Third generation TKIs have shown superior efficacy in the front-line setting and have become standard of care. A better understanding of mechanisms of treatment failure and disease relapse will be required to develop novel therapeutic strategies to further improve patient outcomes in the future.

KW - EGFR

KW - NSCLC

KW - resistance mechanisms

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85063882481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063882481&partnerID=8YFLogxK

U2 - 10.1080/14728214.2018.1558203

DO - 10.1080/14728214.2018.1558203

M3 - Review article

C2 - 30570396

AN - SCOPUS:85063882481

VL - 24

SP - 5

EP - 16

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -